Enteris to Present at BioCentury’s Future Leaders

Enteris BioPharma to Present at the 24th Annual Future Leaders in the Biotech Industry Conference

Boonton, NJ – March 30, 2017 – Enteris BioPharma, Inc., a biotechnology company developing innovative drug products built around its proprietary delivery technologies, today announced that Joel Tune, Chief Executive Officer and Executive Chairman of Enteris BioPharma, will present at the 24th Annual Future Leaders in the Biotech Industry Conference being held April 7, 2017, at the Millennium Broadway Hotel & Conference Center in New York City.

Mr. Tune will present Enteris’ corporate growth strategy and its focus on developing orally delivered peptide therapeutics for a broad range of treatment indications. Since its founding in 2013, Enteris has advanced multiple internal and external programs leveraging its Peptelligence^® platform to enable the safe delivery of peptide-based therapeutics with low oral bioavailability.

Event: 24th Annual Future Leaders in the Biotech Industry Conference
Date: Friday, April 7, 2017
Time: 10:30 a.m. (Eastern Time)
Location: Millennium Broadway Hotel & Conference Center – Room 508

About Enteris BioPharma

Enteris BioPharma, Inc. is a privately held, New Jersey-based biotechnology company offering innovative formulation solutions built around its proprietary drug delivery technologies. The Company’s proprietary oral delivery technology – Peptelligence^® – has been the subject of numerous feasibility studies and active development programs, several of which are in late stage clinical development. Additionally, Enteris BioPharma is advancing an internal product pipeline of oral tablet reformulations of drug products that address significant treatment opportunities for which there is no oral delivery option. Enteris BioPharma’s most advanced internal product candidate, Ovarest^® (oral leuprolide tablet), is a Phase 2a-ready oral peptide, being developed for the treatment of endometriosis. For more information on Enteris BioPharma and its proprietary oral delivery technology, please visit http://www.EnterisBioPharma.com.